



## QUALITY OF TYPE 2 DIABETES CARE BASED ON BLOOD PRESSURE CONTROL IN SUB-SAHARA AFRICA: A SYSTEMATIC REVIEW

Salihu D.A<sup>1</sup>, Gyang M.D<sup>1</sup>, Gyang B.Z<sup>1</sup>, Meshak D.J<sup>1</sup> and Bulus J<sup>2</sup>

<sup>1</sup>Department of Family Medicine, Jos University Teaching Hospital Jos, Plateau State, Nigeria

<sup>2</sup>Department of Family Medicine, Plateau State Hospital Jos, Plateau State, Nigeria

### ARTICLE INFO

#### Article History:

Received 13<sup>th</sup> September, 2021

Received in revised form 11<sup>th</sup>

October, 2021

Accepted 8<sup>th</sup> November, 2021

Published online 28<sup>th</sup> December, 2021

#### Key words:

Type 2 Diabetes Mellitus, Blood Pressure, Sub-Sahara Africa

### ABSTRACT

**Background:** Diabetes Mellitus is an increasing medical problem in Sub-Saharan Africa (SSA). Current evidence suggests an epidemic proportion of this condition in this developing region, largely due to increasing urbanization and epidemiological transition.

There are suggestions that the quality of diabetes care in Africa is suboptimal. However, there is unclear evidence to substantiate these claims. There was the need to systematically assess and summarise the existing evidence on quality of care among patients with type 2 diabetes mellitus (T2DM), whilst identifying any gaps in information and exploring possible barriers to care in a SSA context. This will provide policy makers and health care providers with a systematic overview of the available evidence on the state of diabetes care in this region from which they can base decision making.

**Aim and Objectives:** The aim of the systematic review was to examine the existing quality of management of type 2 diabetes in SSA by addressing the following questions:

- How good is the current control of type 2 DM in SSA based on indicator outcome of blood pressure?
- Have implemented strategies, treatment or interventions improved the outcome of type 2 DM in Sub-Saharan African countries?

**Methods:** This study was a systematic review of quantitative studies. The population comprised people with type 2 diabetes in sub-Saharan Africa. All ages, gender, ethnicities irrespective of race, residence, locality, immigration status, educational background and socio-economic status were included. The studies included cross-sectional studies, experimental, quasi-experimental studies, observational studies and review papers. Only full papers as opposed to abstracts were included in the review. Conference proceedings, editorials and case reports were excluded. Two databases were explored to develop search strategies – MEDLINE via Pubmed (1946 to February 2013) and EMBASE via Ovid (1974 to April 2013). Terms such as hypertension and blood pressure, and terms related to these were used in the search strategy. The search included searching reference lists of derived papers and contacting experts. Data on measures of blood pressure control as primary outcome of interest were extracted and summarised upon. Secondary outcomes included process measures like the frequency of blood pressure levels documentation. Duration of diagnosed diabetes and assessment of diabetes complications were considered. The interventions or implementation strategies within studies or data collected on these were also assessed. Study quality was assessed based on components in a quality assessment tool from the Effective Public Health Practice Project.

**Results:** Eleven published studies were identified and included in the review. These were all cross sectional studies. Education on diabetes management and prevention of complications seemed to be the most consistent intervention carried out, followed by drug treatment, then dietary measures. In most studies less than 40% (Between 15.6% and 35.1%) had target systolic BP value of 130mmHg and/or diastolic value of 80 mmHg.

**Conclusion:** This review found the quality of care of type 2 diabetes based on blood pressure control, to be sub-optimal in sub-Sahara African countries. Therefore, quality of care needs to be improved upon in this region. It is likely that several interventions, mainly secondary preventive strategies, and implementation strategies identified would improve quality of care in this region. Targeted interventions and strategies specific to the local populace would be beneficial. Other forms of interventions like primary preventive strategies can be useful and may need to be investigated. Barriers to good diabetes management should also be taken into consideration when looking at factors impeding quality of care.

Copyright©2021 Salihu D.A et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### INTRODUCTION

The World Health Organisation (WHO) defines Diabetes mellitus as a metabolic disorder characterized by prolonged

hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both [1]. Type 2 diabetes is responsible for over 90% of diabetes cases in Sub-Saharan Africa [2,3]. T2DM is usually due to insulin resistance or reduced insulin

\*Corresponding author: Salihu D.A

Department of Family Medicine, Jos University Teaching Hospital  
Jos, Plateau State, Nigeria

sensitivity, combined with reduced insulin secretion [4]. T2DM may go unnoticed for years because visible symptoms are typically mild, non-existent or sporadic and severe long term complications may occur. T2DM may develop due to an interplay between genetic and environmental factors such as high calorie diet and low physical activity. Exposure to smoking, alcohol and some medications are also possible causes. This systematic review considered T2DM due to the magnitude of people T2DM affects compared to T1DM. Therefore, the public health implications of poor T2DM management and control are likely to be greater.

Worldwide, there was an estimated of 171 million individuals with T2DM in 2000. This figure is predicted to increase to 366 million by 2030 [5]. In their systematic review, Sobngwi and colleagues [6], noted the prevalence of diabetes from 1% in rural areas to 6% in urban areas of Africa. In their systematic review on the epidemiology and public health implications of diabetes in sub-Saharan Africa, Hall *et al* [7] reported that the population prevalence proportion ranged from 1% in rural Uganda to 12% in urban Kenya.

Diabetes Mellitus is an increasing medical problem in Sub-Saharan Africa. Current evidence suggests an epidemic proportion of this condition in this developing region, largely due to increasing urbanization and epidemiological transition [5,6,8,9]. The availability of prevalence data on diabetes for sub-Saharan Africa is very limited. It was projected that there would be an increase of 98% in patients with diabetes every decade and about 23.9 million people could have diabetes in SSA by 2030 [5,6].

Type 2 diabetes mellitus, with its attending complications, has a negative impact on the quality of life of an individual or his family and health care resources (finances, manpower and infrastructure) are usually strained [10]. Treatment of patients and management of complications will imply additional costs to individuals, families and the government. The increased risk of morbidity and mortality in people with diabetes is mainly due to the fact that diabetes is associated with microvascular and macrovascular complications. For example, Mbanya and Sobngwi [11] showed that 16-55% of individuals with diabetes in Africa had retinopathy and newly diagnosed patients with T2DM accounted for 21-25% of this population. This suggests that individuals with complications at diagnosis have been undiagnosed for long periods with poor blood glucose control. This further shows that T2DM care in SSA is sub-optimal. The highest prevalence of retinopathy was observed in populations with the poorest blood glucose control [11]. Nephropathy was associated with poor blood glucose control, high blood pressure and retinopathy while peripheral neuropathy usually occurred after diagnosis of T2DM [11]. The same study reported that in Tanzania, the treatment of diabetic complications represented 30.8% of the total costs of outpatient care in a major hospital in the capital city. The yearly expenditure per patient was US \$138 and this was 19 times more than each government spending on health at an average exchange rate [11].

Macrovascular complications occur mostly in patients with T2DM, or as part of metabolic syndrome X which comprises dyslipidemia, hypertension and central obesity. These can all act to increase the risk of cardiovascular disease [12]. T2DM patients are at higher risks of developing cerebrovascular disease, coronary artery disease and cardiomyopathy

[11,13,14]. There is evidence to suggest an increased risk of cardiovascular events in African population with an increased prevalence of dyslipidaemia [11,15].

Risk factors that may be contributing to the increasing prevalence of T2DM in SSA are similar to those effecting T2DM rates worldwide. In a modelling study explaining the increase in diabetes prevalence and plasma glucose in Mauritius [16], findings suggested that most of the change in prevalence was due to modifiable factors and not due to factors like change in mortality rates.

Modifiable risk factors include cultural and social changes. Therefore, poor dietary habits, sedentary lifestyles, obesity and other unhealthy behaviours could increase the risk of developing T2DM, worsen the disease or increase the risk of complications. Non modifiable risk factors include an ageing population and ethnicity [17,18]. There is the need to prevent or delay the risk or progression of complications associated with these changes [19, 20]. Healthier dietary changes, increased physical activity, avoidance of cigarette smoking or tobacco, and structured education are interventions that have been recommended. Medications may also be useful. These measures aim at controlling three important indicators of care in T2DM patients: blood glucose, blood pressure and lipids [20]. However, studies have shown that in spite of recent (2007) achievements in control of these indicators in diabetic adults, less than 15% met the targets for all three indicators at the same time [21,22]. These may suggest that the recommended interventions or strategies are poorly administered or utilized. Consequently, improvements in the quality of care among T2DM patients may be impaired.

The Diabetes Foundation (DF) Report on Implementing National Diabetes Programmes in Sub-Saharan Africa [23] explains that the current approaches to management of diseases in SSA concentrate on acute infectious diseases. However, similar approaches cannot be used for chronic diseases like diabetes. Continuous self-management is essential for diabetic patients and there is also the need for regular long-term follow up and treatment. As mentioned earlier, there are currently several interventions that are aimed at improving the quality of care of diabetic patients in order to achieve improved outcomes [24]. However, whether these interventions achieve desirable control of T2DM is still uncertain. Uncertainty here may be as a result of poor follow up of outcomes. For example, clinical outcome like blood pressure as a measure of control which this systematic review took into cognisance. Furthermore, interventions may not work due to barriers like poor feasibility, efficacy or acceptability. There are current gaps between ideal and actual interventions in management among clinicians [24, 25]. Poor self-management by patients and inadequate health care delivery due to clinician behaviour may contribute to inadequate control of these indicators [21,26]. Changing patients' behaviour on healthy lifestyles may still remain a challenge.

Achieving good quality of care for diabetic patients may involve some key areas that have been suggested in the Diabetes Foundation Report [23]. These include preventive strategies – primary, secondary and tertiary, availability of diagnostic tools and infrastructure, drug procurement and supply, accessibility and affordability of medicines and care, health care workers techniques to health care delivery, adherence to management strategies by patients, patient

education and empowerment, community involvement and diabetes associations, and a positive policy environment [23]. In view of the increasing prevalence, and health and economic implications in the management of patients with T2DM, it is important that effective strategies are implemented early.

There are suggestions that the quality of diabetes care in Africa is suboptimal. However, there is unclear evidence to substantiate these claims [17]. An insight into the extent of the disease burden is crucial for effective advocacy and action in this region. However, currently, there has been little effort to provide policy makers and health care providers with a systematic overview on the available evidence on the state of diabetes care in SSA [17]. Consequently, there was the need to systematically assess the quality of care among patients with T2DM in existing studies with the objective of summarizing existing evidence, identifying the gaps and exploring the barriers to care in the SSA context. For example the IDF guidelines for type 2 diabetes reports that screening for T2DM has important implications for individual health and public health policy [27]. While early detection and treatment of diabetes may minimize complications, there are no direct evidence as to whether or not this is beneficial to individuals. It was also documented that published national guidelines for management of type 2 diabetes come from relatively resource-rich countries and may be of limited practical use in less well-resourced countries like those in Africa.

Scoping of the literature showed that circumscribing the systematic review to a single research question and to a more specific region or type of setting may yield a very limited number of studies, thus rendering the systematic review implausible. Consequently, we set out to address more than one interrelated question on diabetes care.

The aim of the review was to examine the existing quality of management of type 2 diabetes in SSA by addressing the following questions:

1. How good is the current control of type 2 DM in SSA based on indicator outcome of blood pressure?
2. Have implemented strategies, treatment or interventions improved the outcome of type 2 DM in Sub-Saharan African countries?

## **METHODOLOGY**

This study is a systematic review of quantitative research upon T2DM in SSA. A systematic review protocol was developed based on the PRISMA reporting guidelines [28]. Being a systematic review with no primary data collection, ethical approval was not required.

### **Study Selection**

#### **Inclusion**

The population comprised people with T2DM in SSA. All ages, gender, ethnicities irrespective of race, residence, locality, immigration status, educational background and socio-economic status were included.

Cross-sectional studies, quasi-experimental studies, experimental studies, observational studies and reviews were included. All studies including blood pressure and/or its control as outcome indicator were included. Papers were limited to those in English. Only full papers as opposed to abstracts were included.

#### **Exclusion**

Case reports were excluded since these, in most cases may not be representative of the target populations under study. For pragmatic purposes, conference proceedings and editorials were excluded. Papers that did not fit the inclusion criteria upon consultation of their titles and abstracts were excluded. Studies presenting data that was only partially available was excluded.

#### **Outcome Measures**

The primary outcome measure was blood pressure levels to assess control. The process measures were the frequency of documentation of blood pressure. Other secondary outcome measures considered included patients screened for diabetes and its complications such as retinopathies and foot abnormalities, monitoring of renal and cardiovascular events and patients educated on the management and prevention of complications. Those taking or administered medications including anti hypertensives were also considered.

#### **Information sources and search strategy**

Two databases were explored - MEDLINE and EMBASE since both are large medical and biomedical databases relevant to the review topic. To enable an extensive search of relevant literature in database to the period of the review, the search in Medline contained articles from 1946 to February 2013 while that from Embase contained articles from 1974 to April 2013. The search was based on population, indicators, comparators and outcomes (PICO) in relation to the review questions. It was carried out using terms from PICO deconstruction of the review questions. The search was carried out by two reviewers. Search strategy developed in one search database (Medline via PubMed) was adapted for a second database (Embase via Ovid) and refined due to possible differences in database MeSH headings or dictionaries. The reference lists of the database-derived papers were searched for relevant studies. Relevant papers were also obtained from an expert on the research topic.

The study titles and available abstracts were first reviewed and assessed against the inclusion criteria to determine eligibility before being completely screened. Two reviewers independently assessed papers for eligibility. Figure 1 shows the flow chart of number of papers identified and screened to those considered eligible and included for review.

#### **Data Extraction and Quality Assessment**

The data was extracted from each study based on 1) study type 2) participant characteristics, 3) country and setting (tertiary, secondary or primary hospital), 4) interventions and implementation strategies assessed, prevalence of complications amongst undiagnosed and newly diagnosed T2DM patients or data collected on these 5) outcomes measures (Tables 1). Data extraction included that of summary statistics within papers.

Tables were modified based on the nature of available evidence. Study quality was assessed based on the strength of evidence from a combination of components in a quality assessment tool from the Effective Public Health Practice Project – EPHPP [29, 30]. However, this tool had its limitations considering the type of studies included in the review. For example, it was difficult assessing blinding techniques and withdrawal to follow-up in cross-sectional studies. Quality

assessment was used to help interpret and explain differences in results across studies.

**Data Synthesis**

A narrative synthesis was used in summarising and explaining findings. Extracted data was systematically grouped and summarised into the types of study and clinical outcomes based on blood pressure control.

**RESULTS**

**Types and characteristics of studies**

Table 1 shows the types and characteristics of studies. Eleven studies were considered eligible and included in the review (Figure 1).

All the papers reviewed were solely cross-sectional studies [31-41]. One cross-sectional study was received in 2008 while the others were carried out from 2002 onwards. There were no studies on primary preventive measures or screening studies. Studies describing mainly secondary preventive measures of T2DM were available for selection.

Except for two studies, all were carried out in tertiary hospitals or medical centres. One study took place in a primary health centre while one study was at specialized clinics. Varying methods involving retrospective review of patients' records, data collection and assessment during the study to prospective methods were used across the studies. One cross-sectional study was comparative [41].

**Table 1** Summary of Type of Study Design, Interventions, Outcome measures and data collected

Ref/Date of Study	Type of Study	Country	Sample Size	Population Characteristics	Intervention/ Implementation strategies/ Data collected	Outcomes Observed/ documented	Main Outcome(s)	Study Limitation
1. Gudina <i>et al</i> /2009	Cross-sectional	Ethiopia	329	-M:F = 1.46:1 Mean (SD) = 48.4 (15.1) -TH	-Diabetes health education -Review of charts for treatment of diabetes/hypertension and causes of admission -Drug treatment for hypertension	-follow-up visits -Mean duration of DM -Assessment of Diabetes related complications -Clinical outcomes	BP	- Poor chart keeping. -study design unable to assess chronic complications
2. Okafor/Ofoegbu 2011	Cross-sectional	Nigeria	233	42.1% males attending diabetic clinic in a TH	Degree of adherence to therapeutic measures	-Duration of DM -Clinical outcomes	BP	No consideration of effect of disease duration and duration of follow-up of patients.
3. Chineye <i>et al</i> /2008	Cross-sectional	Nigeria	531 (95.4% T2DM)	39.4% Males, Multicentre study including 7 tertiary health centres	-Clinic visits and clinical assessment -Patient self-monitoring -Diabetes education received by patient -Use of medications -Eye examination, lower limb examination. -cerebral stroke, neuropathy, myocardial infarction, renal failure	-Mean duration of DM -Frequency of clinic visits and assessment -Adherence to dietary measures and exercise -Assessment of diabetic complications and cardiovascular risk factors	BP	
4. Joseph <i>et al</i> 2009/10	Cross-sectional	Cameroun	205	Male=43.6%. Mean Age=57 Age Range= 29-85 Tertiary health centre	Regular chronic care with follow-up appointments	-Drug treatment rates -Mean duration of diagnosed diabetes -Assessment of cardiovascular risk factors and diabetic complications BP control	BP	Selective non-random sample of participants that may not be representative of the population
5. Isezuo SA/2002	Cross-sectional	Nigeria	254	Males=154(60.6%) Outpatients and Inpatients in a TH	Laboratory assessment of components of the metabolic syndrome	Metabolic syndrome, hypertension, obesity, microalbuminuria, hyperuricaemia	BP	Data collection methods not clearly stated
6. Christopher OA.	Cross-sectional	Nigeria	218	Males=58.7% Mean Age=52±5.8yrs. Range=36-62yrs	-Use of medications -Dietary measures -Hypertension(HTN)	Duration of diabetes. Drug therapy. BMI, HTN, Microalbuminuria	BP	Statistical methods not clear
7. Berhane <i>et al</i>	Cross-sectional	Eritrea	429	Age=57.4±11.8	-Dietary treatment -Medications, tablets or Insulin	-Assessment of complications -HTN	BP	Poor standardized BP levels
8. Vezi/Naido 2002/03	Cross-sectional	South Africa	62	Age (Range) in years Males:49 (34-72) Females:50(33-69)	-Routine clinical examination and follow-up viits	-Assessment of liver, renal and thyroid function tests, -Hypertensivelevels -Obesity	BP	-Methodology not clear
9. Marloes <i>et al</i> 2005	Cross-sectional	South Africa	247		-Review of medical records -Diabetes education -Medical treatment, diet -Regular visits	-Duration of diabetes -Assessment of cardiovascular risk factors and diabetes complications	BP	Potential for non-standardization of Instruments (ie questionnaire) used and non standard measurement of reported outcome
10. Isezuo <i>et al</i> , 2003	Cross-sectional	Nigeria	120		Use of medications	-Duration of diabetes and HTN - Hypertensive levels -Obesity	Differences in clinical outcome of BP between groups	Unclear sampling method. Poorly discussed population characteristics
11. Sobngwi <i>et al</i>	Cross-sectional Multi centric	Tanzania, Kenya, Cameroun, Ghana, Senegal, Nigeria	2352	Adult population registered for management of DM Mean age=53.0±16.0	-Medications -Treatment of hypertension	-Duration of diabetes -Assessment of Cardiovascular risk factors and diabetes complications -Clinical outcomes	BP, BMI	Lack of standardization of biological measurement Study was limited to best level of care.




Figure 1 Flow chart of study selection process

Populations specifically included type 2 diabetic patients in some studies while other studies consisted of mixed diabetic populations that were predominantly type 2 diabetics. The sample size of the studies was within the range of 62 [38] to 2352 [40]. While some studies predominantly consisted of males, other studies had more female patients. The average age within studies varied between 48 years to 56 years with age ranges also varying.

The interventions, implementation strategies and outcome measures, as well as data collected on these are summarized in Table 1 below.

The main outcome measure was blood pressure control based in all the studies. The interventions included diabetes education, lifestyle modifications and the use of medications. A clinical algorithm was used to carry these out. Across the cross sectional studies [31-41], data on interventions and implementation strategies were collected using questionnaires, interviews or review of records. Data on education on diabetes seemed to be the most consistent, followed by drug treatment, then dietary measures. Patient self-monitoring, the use of treatment algorithms, review of charts, clinic visits and laboratory assessments were some of the strategies implemented for diabetes control. The mean duration of diabetes, degree of adherence to therapeutic measures, diabetic complications (e.g retinopathies, neuropathies) and cardiovascular risk factors (such as frequency of cigarette smoking) were secondary outcome measures assessed. The studies generally did not consider clinical guidelines. To assess blood pressure control, reference values of the indicator outcomes were based on the ADA and IDF guidelines.

**Blood pressure Control**

Blood pressure control was identified in 11 studies summarised in Table 6 below.

**Summary of Blood Pressure (BP) Control**

No study reported the frequency of documentation as a process measure but frequency of screening of diabetes complications and cardiovascular risk factors that included hypertension were variably documented in some of the studies.

There were variations in hypertension rates across the studies. Hypertension also had varied definitions. Patient populations included those with and without hypertension in some studies. For example, in one study [31] good BP control was found in 6.8% of known hypertensive patients (44.4% of the patients studied). Forty one percent of undiagnosed hypertensives in the same study had poor BP control. Mean SBP levels ranged from 124.1 mmHg to 178.9 mmHg.

Ref/dates of study	Setting	Country	Population characteristics				Outcomes and results				
			Sample size	% male	Age (years)		BP level (mmHg)		Process outcomes (frequency of documentation)		
					Mean (SD)	Range	Mean (SD) SBP/DBP	BP <130/80	BP 130/80	BP <130/80	BP 130/80
1.Gudina <i>et al</i> 2009	TH	Ethiopia	329	M:F 1.46:1	48.4 (15.1)	15-82	124.1(17.2)/80.7(9.4)	6.8% in known hypertensives	41% in undiagnosed hypertensives	64.1% overall	
2.Okafor/Ofoegbu, 2011	TH	Nigeria	233	42.1			134.6(22.8)/80.4(21.9)		51.9% overall	SBP=46.6%	DBP=32%
3.Chineye <i>et al</i> , 2008	TH	Nigeria	531	39.4	57.1 (12.3)		142(23.7)/80.7(12.7)	17.2%			
4.Joseph <i>et al</i> , 2009/10	TH	Cameroon	205	43.6	57	29-85	135.9(21.1)/80.6(12.1)	35.1%			
5.Christopher OA, 1999-2001	TH	Nigeria	218	58.7	52(5.8)	36-62	147.5(15.5)/93(9.5)				
6. Isezuo SA	TH	Nigeria	254	60.6			135.0(21.1)/83.1(11.8)				
7.Berhane <i>et al</i> -Received 2008	TH	Eritrea	429		57.4	11.8	127.7/83.8		55.2%		
8.Vezi/Naidoo 2002-2003	TH	South Africa	62		M-49 F-50	34-72 33-69	Males = 146/92, Females=153/89		75%		
9.Marloes <i>et al</i> 2005	PHC	South Africa	247		58.2 (10.9)	30-85		15.6%			
10.Isezuo <i>et al</i> 2003	TH	Nigeria Tanzania Kenya	120				178.9(18.8)/99.6(19.8)				
11.Sobngwi <i>et al</i> 2008	Specialized Clinics	Cameroon Ghana Senegal Nigeria	2352				139(24)/82(13)	21%			

BP=Blood Pressure SBP=Systolic Blood Pressure DBP=Diastolic Blood Pressure SD=Standard Deviation  
TH=Tertiary Hospital PHC=Primary Health Centre

Eight out of the 11 studies had a mean SBP range of 134.6 [32] to 153 mmHg [33] and corresponding mean DBP range of 80.4 mmHg to 92mmHg. Generally, in most studies less than 40% (Between 15.6% and 35.1%) had target systolic BP value of 130mmHg and/or diastolic value of 80 mmHg. In one study [159], 75% of patients had a poor BP control.

Nine studies were from tertiary institutions, one from a primary health centre and one from specialized clinics.

## **DISCUSSION**

The quality of care of type 2 diabetes in sub-Saharan Africa based on blood pressure control indicator was found to be suboptimal in this review. This is in view of the fact that within studies, less than 50% of patients met the targets for this clinical outcome. Although studies were carried out more in tertiary health centres than primary health centres, from the studies, it may be inferred that blood pressure control were better achieved in the tertiary centres.

All the studies were cross-sectional studies, were sometimes difficult to interpret and were assessed to be of moderate to low quality mainly due to methodological discrepancies and poor reporting. Although multiple interventions and implementation strategies were documented in settings where healthcare was mainly developing, these may have still improved clinical outcomes.

Due to the differences in genetic make-up, study settings, health care facilities, disparities in the interventions and implementation strategies, clinical guidelines for management and target levels, it is unlikely that interventions would be equally effective across the regions studied. In addition, baseline measures were unlikely to be equal and may have been impacted by other diseases of high prevalence within these regions. Similar findings on interventions, process and clinical outcomes have been reported in studies elsewhere. This is in keeping with many national guidelines that include treatment algorithms, which are based on available evidence and local availability and prescribing regulations [44]. The IDF updated guideline includes a generic algorithm which is intended for adaptation by countries for local use [44]. Oral medications were commonly used in some of the reviewed studies [33,35,37,39,41,42]. Regular clinic visits, patient self-monitoring and clinic records and charts, although inconsistent in this review may be effective measures implored in developed societies and poor utilisation of these interventions may have effectively contributed to the suboptimal clinical outcome seen in this study. The clinical outcome documented in this review was similar to the review done in the Co-operation council for the Arab States of the Gulf [45]. However, blood pressure levels were generally higher when compared to some reports from studies from the UK [46-48], USA [49,50] and Australia [51]. It is of note that these countries operate systems with higher levels of care and some of the clinical outcomes of this review met the upper limits of the UK Quality and Outcomes Framework targets. Process outcomes were probably more frequently documented in other countries than the studies in this review. Mean duration of diabetes, and assessment of cardiovascular risk factors and complications are process measures and outcomes also obtainable in developed societies [46,49].

Although this study did not actively seek barriers to improved care in these regions, it may suffice here to say that the

suboptimal indicator levels seen in this review may have, to a large extent, been contributed by these barriers. From the studies, these would include poor adherence to therapeutic measures, poor health seeking behaviours, poor affordability and accessibility of quality health care services, lack of effective use of medications and health care facilities, and difficulties making lifestyle changes. These are mainly patients' related factors. From the reviewed studies, clinician factors would include poor registration of patients, poor chart keeping, poor emphasis on diabetes education and oversight in testing or managing risk factors. However, compared to other reviews on interventions and barriers to diabetes management [53], patients' and clinicians' attitudes and beliefs, cultural factors and organisational factors were not explicitly stated.

The heterogeneity of the reviewed studies was a major limitation. The populations varied and there were disparities in outcome measures. Different study settings were used with varying health care systems. The absence of a universally accepted definition of high quality care and diabetes care in particular as well as the diversity in diabetes care programmes prevented meaningful comparisons to be made. The critical appraisal of complex interventions was difficult and building on evidence was limited. Only few sub-Saharan countries were included in the review. Most of the clinical outcomes were of varied definitions with no standardisation. Primary prevention programmes were generally not included in the reviewed studies. A large number of the studies reviewed were cross-sectional studies and they were of moderate to low quality. There were mostly methodological discrepancies. However, no study was excluded based on difficulty assessing quality. There was a relatively low number of papers returned by the different searches from each database and consequently fewer papers eligible for review.

## **CONCLUSION**

This review found the quality of care of type 2 diabetes based on blood pressure levels to be sub-optimal in sub-Saharan African countries. Therefore, quality of care needs to be improved upon in this region. High quality studies were not identified in the study and this may have impaired quality assessment of the studies. Better quality of research in this region would therefore be necessary if future research needs to be of relatively high standard.

This study noted several interventions, mainly secondary preventive strategies that may improve quality of care in this region. It is likely that the implementation strategies identified in this review could contribute effectively in improving quality of care. Other forms of interventions like primary preventive strategies can be useful and may need to be investigated. Targeted interventions and strategies specific to the local populace would be beneficial. Barriers to good diabetes management should also be taken into consideration when looking at factors impeding quality of care.

It would be important to consider the interventions and implementation strategies reviewed in the various health care systems in this region to improve quality of care. National, regional and international organisations involved in diabetes care and setting guidelines could aim at standardizing process and clinical outcomes that would be useful in making comparisons and quality of care auditing.



## References

1. Alberti K.G, Zimmet P.Z. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mellitus. Provisional Report of a WHO Consultation. *Diabetic Medicine*. 1998;15:539-53.
2. Levitt NS: Diabetes in Africa: epidemiology, management and healthcare challenges. *Heart* 2008, 94(11):1376-82.
3. Lawrence MT ,Stephen JM, Maxine AP. Diabetes Mellitus & Hypoglycemia. *Current Medical Diagnosis & Treatment* 2004, 43rd edition, p. 1146.
4. Report of expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 1997;20:1183-97.
5. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004 May;27(5):1047-53.
6. Sobngwi E, Mauvais-Jarvis F, Vexiau P, Mbanya JC, Gautier JF. Diabetes in Africans. *Diabetes Metab*. 2001;27:628-34.
7. Hall *et al*: Diabetes in Sub Saharan Africa 1999-2011: Epidemiology and public health implications, a systematic review. *BMC Public Health* 2011 11:564.
8. Lekoubou A, Awah P, Fezeu L, Sobngwi E, Kengne AP. Hypertension, diabetes mellitus and task shifting in their management in sub-Saharan Africa. *Int J Environ Res Public Health*. 2010 Feb;7(2):353-63.
9. Federation ID. *Diabetes Atlas*. 4th ed. International Diabetes Federation. 2009.
10. Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. *Heart*. 2008;94(11):1376-82.
11. Mbanya J-C, Sobngwi E. Diabetes microvascular and macrovascular disease in Africa. *European Journal of Cardiovascular Risk*. 2003;10(2):97-102.
12. Almdal T SHJJVH. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13 000 men and women with 20 years of follow-up. *Archives of Internal Medicine*. 2004;164(13):1422-6.
13. Obesity: preventing and managing the global epidemic. World Health Organization technical report series. 2000;894.
14. Mbanya JCN, Minkoulou EM, Salah JN, Balkau B. The prevalence of hypertension in rural and urban Cameroon. *International journal of epidemiology*. 1998;27(2):181-5.
15. Erasmus RT, Bojuwoye BJ, Olukoga O, Adewoye H. Plasma HDL cholesterol, triglyceride and total cholesterol levels in non insulin treated Nigerian diabetics. *Tropical and geographical medicine*. 1989;41(3):238.
16. Magliano, Dianna J, *et al*. "Explaining the increase of diabetes prevalence and plasma glucose in Mauritius." *Diabetes care* 35.1 (2012): 87-91.
17. Levitt NS. Diabetes in Africa: epidemiology, management and healthcare challenges. *Heart*. 2008;94(11):1376-82.
18. WHO. World Health Organization. Prevention of diabetes mellitus. Report of a WHO Study Group. Geneva: World Health Organization; 1994.
19. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. *Diabet Med*. 2007 May;24(5):451-63.
20. S. C. Optimal management of type 2 diabetes: the evidence, review article. *Diabetes, Obesity and Metabolism*. 2012; 14(1):3-8.
21. Nam S, Chesla C, Stotts NA, Kroon L, Janson SL. Barriers to diabetes management: patient and provider factors. *Diabetes Res Clin Pract*. 2011 Jul;93(1):1-9.
22. Hoerger TJ, Segel J E, Gregg EW, Saaddine JB. Is Glycemic Control Improving in U.S.Adults? *Diabetes Care*. 2008;31(1).
23. International Insulin Foundation. Beran, D. The Diabetes Foundation Report on implementing national diabetes programmes in sub-Saharan Africa; 2006.
24. Renders CM, Valk GD, Griffin SJ, Wagner EH, Assendelft WJ. Interventions to Improve the Management of Diabetes in Primary Care, Outpatient, and Community Settings A systematic review. *Diabetes Care*. 2001;24(10):1821-33.
25. Tricco A.C, Ivers N.M, Grimshaw J.M, Moher D. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. *The Lancet*. 2012;379(16):2252-61.
26. Aljaseem LI, Peyrot M, Wissow L, Rubin RR. The Impact of Barriers and Self-Efficacy on Self-Care Behaviors in Type 2 Diabetes. *The Diabetes Educator*. 2001;27(3):393-404.
27. International Diabetes Federation. *Global Guidelines for Type 2 Diabetes*, 2012.
28. Moher, David, *et al*. "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement." *Annals of internal medicine* 151.4 (2009): 264-269.
29. Hamilton ON. Quality Assessment Tool for Quantitative Studies. 2008 13 April 2010 [cited 2012 21 November]; Available from: <http://www.nccmt.ca/registry/view/eng/14.html>.
30. Thomas, BH, *et al*. "A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions." *Worldviews on Evidence Based Nursing* 1.3 (2004): 176-184.
31. Gudina, Esayas K., *et al*. "Assessment of quality of care given to diabetic patients at Jimma University Specialized Hospital diabetes follow-up clinic, Jimma, Ethiopia." *BMC endocrine disorders* 11.1 (2011): 19.
32. Okafor, CI, and EN Ofoegbu. "Control to goal of cardiometabolic risk factors among Nigerians living with type 2 diabetes mellitus." *Nigerian Journal of Clinical Practice* 15.1 (2012).
33. Chinenye, Sunday, *et al*. "Profile of Nigerians with diabetes mellitus–Diabcare Nigeria study group (2008): Results of a multicenter study." *Indian journal of endocrinology and metabolism* 16.4 (2012): 558.
34. Mekong, Joseph O, *et al*. "Cardiovascular Preventative Therapies and Outcomes of Care Among Urban Sub-Saharan Africans with Type 2 Diabetes: A Cross-Sectional Study in Cameroon." *JCOM* 19.10 (2012).
35. Alebiosu, Christopher Olutayo and B. OlatundeOdusan. "Metabolic syndrome in subjects with type-2 diabetes mellitus." *Journal of the National Medical Association* 96.6 (2004): 817.

36. Isezuo, S A., and E. Ezunu. "Demographic and clinical correlates of metabolic syndrome in Native African type-2 diabetic patients." *Journal of the National Medical Association* 97.4 (2005): 557.
37. Seyum, Berhane, *et al.* "Profile of patients with diabetes in Eritrea: results of first phase registry analyses." *Acta diabetologica* 47.1 (2010): 23-27.
38. Vezi, Z.B, and Naidoo DP. "Dyslipidaemia among black patients with type 2 diabetes." *Cardiovascular journal of South Africa: official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners* 16.4 (2005): 194.
39. Van de Sande, Marloes, Hanneke Dippenaar, and Guy EHM Rutten. "The relationship between patient education and glycaemic control in a South African township." *Primary Care Diabetes* 1.2 (2007): 87-91.
40. Sobngwi, Eugene, *et al.* "Type 2 diabetes control and complications in specialised diabetes care centres of six sub-Saharan African countries: The Diabcare Africa study." *Diabetes research and clinical practice* 95.1 (2012): 30-36.
41. Isezuo SA., Badung SLH, and Omotoso ABO. "Comparative analysis of lipid profiles among patients with type 2 diabetes mellitus, hypertension and concurrent type 2 diabetes, and hypertension: a view of metabolic syndrome." *Journal of the National Medical Association* 95.5 (2003): 328.
42. Erasmus RT, *et al.* "Assessment of glycaemic control in stable type 2 black South African diabetics attending a peri-urban clinic." *Postgraduate medical journal* 75.888 (1999): 603-606.
43. Price C, *et al.* "Long-term glycaemic outcome of structured nurse-led diabetes care in rural Africa." *QJM* 104.7 (2011): 571-574.
44. Colagiuri, Stephen. "Optimal management of type 2 diabetes: the evidence." *Diabetes, Obesity and Metabolism* 14.s1 (2012): 3-8.
45. Alhyas, Layla, *et al.* "Quality of type 2 diabetes management in the states of the Co-operation Council for the Arab States of the Gulf: a systematic review." *PloS one* 6.8 (2011): e22186.
46. Calvert M, Shankar A, McManus RJ, Lester H, Freemantle N (2009) Effect of the quality and outcomes framework on diabetes care in the United Kingdom: retrospective cohort study. *BMJ* 338: b1870.
47. Millett C, Car J, Eldred D, Khunti K, Mainous AG, *et al.* (2007) Diabetes prevalence, process of care and outcomes in relation to practice size, caseload and deprivation: national cross-sectional study in primary care. *J R Soc Med* 100: 275–283.
48. Khunti K, Gadsby R, Millett C, Majeed A, Davies M (2007) Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes. *Diabetic Med* 24: 1436–1441.
49. Saaddine JB, Cadwell B, Gregg EW, Engelgau MM, Vinicor F, *et al.* (2006) Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 1988–2002. *Annals of Internal Medicine* 144: 465–474.
50. Grant RW, Buse JB, Meigs JB (2005) Quality of Diabetes Care in U.S. Academic Medical Centers: Low rates of medical regimen change. *DiabetesCare* 28: 337–442.
51. Wan Q, Harris MF, Jayasinghe UW, Flack J, Georgiou A, *et al.* (2006) Quality of diabetes care and coronary heart disease absolute risk in patients with type 2 diabetes mellitus in Australian general practice. *Qual Saf Health Care* 15: 131–135.
52. QOF clinical indicators 2013/14. [http://www.eguidelines.co.uk/eguidelinesmain/external\\_guidelines/qof.php](http://www.eguidelines.co.uk/eguidelinesmain/external_guidelines/qof.php). Accessed 26/01/14.
53. Nam, Soohyun, *et al.* "Barriers to diabetes management: patient and provider factors." *Diabetes research and clinical practice* 93.1 (2011): 1-9.

**How to cite this article:**

Salihu D.A *et al* (2021) 'Quality Of Type 2 Diabetes Care Based On Blood Pressure Control In Sub-Sahara Africa: A Systematic Review', *International Journal of Current Advanced Research*, 10(12), pp. 25583-25590.  
DOI: <http://dx.doi.org/10.24327/ijcar.2021.25590.5107>

\*\*\*\*\*